CANG vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 21, 2026

CANG

40.8
AI Score
VS
HIVE Wins

HIVE

47.3
AI Score

Investment Advisor Scores

CANG

41score
Recommendation
HOLD

HIVE

47score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CANG HIVE Winner
Revenue 688.08M 297.79M CANG
Net Income -621.95M -148.45M HIVE
Net Margin -90.4% -49.8% HIVE
ROE -156.6% -28.0% HIVE
ROA -54.9% -23.2% HIVE
Total Assets 1.13B 639.15M CANG
Cash 41.24M 23.11M CANG
Current Ratio 0.71 1.10 HIVE

Relative Price Performance (Last 90 Days)

CANG 1M: -55.6% · 3M: -29.6% HIVE 1M: -33.8% · 3M: -33.1%

Current Technical Phase

CANG

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 32

RSI (14): 32.3 · Price: $1.13

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 31

RSI (14): 31.1 · Price: $1.93

Fundamentals Snapshot

Metric CANG HIVE
Market Cap — —
Forward P/E -8.9 -4.1
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.3% 0.7%
Gross Margin -0.1% 0.4%
Operating Margin -0.5% -0.6%
EPS -15.93 -1.32
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.